Trial intelligence / Profile preview

NAPA-3 alfimeprase in acute peripheral arterial occlusion

2005-004901-27Phase 3Terminated

Sponsor
Nuvelo
Start
Dec 2005
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in Acute limb ischaemia (ALI) comparing Alfimeprase with Placebo (2 arms). Primary endpoint: 30-day open vascular surgery-free rate. Started Dec 2005; status: terminated.

02

Drugs

alfimeprase
03

Conditions

Acute limb ischaemia (ALI)

Beyond the preview

Go deeper on 2005-004901-27.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-004901-27.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call